TIM-3

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

38 citing papers in PubMed, 44 citations in OpenAlex.

1. Immune-Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy.MedComm · 2026
   Review
2. Spatial transcriptomics identifies a suppressive, T-cell-excluded tumor microenvironment in extramedullary myeloma.Blood advances · 2026
   Article
3. d-serine as a metabolic immune checkpoint in the tumour microenvironment.EBioMedicine · 2026
   Article
4. Tumor-draining lymph nodes shape the tumor microenvironment through enrichment of tumor-reactive effector-exhausted CD8Signal transduction and targeted therapy · 2026
   Article
5. Spatial profiling of tissue-resident memory T cells reveals stromal IL-15 niches and a paradoxical CD103⁺ phenotype predicting survival in oral squamous cell carcinoma.BMC cancer · 2026
   Article
6. The impact of T cell exhaustion in hematopoietic stem cell transplantation.Stem cell research & therapy · 2026
   Review
7. CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.Blood · 2026
   Article
8. T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
   Review
9. β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
   Article
10. The AICL-KLRF1 axis supports CD4-CD8 T cell communication and cytokine competence in pre-exhausted CD8EMBO reports · 2026
    Article
11. Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.Research square · 2026
    Article
12. Balancing Intrinsic and Extrinsic Factors in CD8Immune network · 2026
    Review
13. Sex Hormones-Mediated Modulation of Immune Checkpoints in Pregnancy and Recurrent Pregnancy Loss.International journal of molecular sciences · 2026
    Article
14. Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.Journal of translational medicine · 2026
    Article
15. A Macrophage/Monocyte-Related Four-Gene Signature for Prognostic Assessment of Uveal Melanoma:Human mutation · 2026
    Article
16. Role of elevation of glycolysis in tumor-associated macrophages in glioblastoma immune evasion and therapeutic implications.PNAS nexus · 2026
    Review
17. AblatingFrontiers in immunology · 2026
    Article
18. EomesoderminImmunity · 2025
    Article
19. Epigenetic reprogramming as the nexus of cancer stemness and therapy resistance: implications for biomarker discovery.Discover oncology · 2025
    Review
20. Serum type III procollagen, procollagen V, tumour necrosis factor-a, interleukin-6 in liver cirrhosis after antiviral treatment.Journal of medical biochemistry · 2025
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

21 authors at 6 institutions in 2 countries.

Funding

Abstract

Indexed as